Path ID: DB00555_MESH_D004827_1
Concepts
| Identifier | Name | Type |
|---|---|---|
| MESH:C047781 | lamotrigine | Drug |
| InterPro:IPR001696 | Voltage gated sodium channel, alpha subunit | GeneFamily |
| GO:0061530 | aspartate secretion, neurotransmission | BiologicalProcess |
| GO:0061535 | glutamate secretion, neurotransmission | BiologicalProcess |
| HP:0020219 | Motor seizure | PhenotypicFeature |
| MESH:D004827 | Epilepsy | Disease |
Relationships
NOTE: predicates are annotated in Biolink Model (v1.3.0)
| Subject | Predicate | Object |
|---|---|---|
| Lamotrigine | NEGATIVELY REGULATES | Voltage Gated Sodium Channel, Alpha Subunit |
| Voltage Gated Sodium Channel, Alpha Subunit | POSITIVELY REGULATES | Aspartate Secretion, Neurotransmission |
| Voltage Gated Sodium Channel, Alpha Subunit | POSITIVELY REGULATES | Glutamate Secretion, Neurotransmission |
| Aspartate Secretion, Neurotransmission | POSITIVELY CORRELATED WITH | Motor Seizure |
| Glutamate Secretion, Neurotransmission | POSITIVELY CORRELATED WITH | Motor Seizure |
| Motor Seizure | POSITIVELY CORRELATED WITH | Epilepsy |
Comment: This drug may also affect GABA-mediated synaptic transmission as listed by DrugBank (https://go.drugbank.com/drugs/DB00555#BE0000013). However, this is contentious and if the drug does modulate GABA it’s not known whether it is as agonist or antagonist due to conflicting data (at best it would be a weak modulation seen in animal models only). Note that the drug could be contraindicated for treatment of seizures as it can exacerbate them, specially the myoclonic type (https://pubmed.ncbi.nlm.nih.gov/9596203/).
Reference:
- https://go.drugbank.com/drugs/DB00555#mechanism-of-action
- https://en.wikipedia.org/wiki/Lamotrigine#Mechanism_of_action
- https://en.wikipedia.org/wiki/Lennox%E2%80%93Gastaut_syndrome#Signs_and_symptoms
- [https://en.wikipedia.org/wiki/Glutamate_(neurotransmitter)#Disease,disabilities,_and_pharmacology](https://en.wikipedia.org/wiki/Glutamate(neurotransmitter)#Disease,_disabilities,_and_pharmacology)